clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-482Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSКлинико-экономическая эффективность применения препарата дапаглифлозин у пациентов с сахарным диабетом 2-го типа в условиях здравоохранения Российской ФедерацииClinical and economic efficiency of treatment with dapagliflozin of patients with type 2 diabetes mellitus in Russian health care conditionshttps://orcid.org/0000-0002-6348-6867ЗыряновС. К.ZyryanovS. K.

Зырянов Сергей Кенсаринович - д. м. н., профессор, зав. кафедрой общей и клинической фармакологии. SPIN-код: 2725-9981

Москва

Zyryanov Sergey -MD, professor, Head of Department of General and Clinical Pharmacology. SPIN code: 2725-9981

Moscow

ДьяковИ. Н.DyakovI. N.

Дьяков Илья Николаевич - к. б. н., Генеральный директор АНО «Научно-практический центр исследования проблем рациональной фармакотерапии и фармакоэкономики». SPIN-код: 1854-0958

Москва

Dyakov Ilya - Candidate of Biological Sciences, General Director Scientific and Practical Centre for rational pharmaceutical management and pharmacoeconomics problems. SPIN code: 1854-0958

Moscow

dyakov.ilya@gmail.comФедеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»РоссияRussian University of Nations’ FriendshipRussian FederationФедеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова»; Автономная некоммерческая организация «Научно-практический центр исследования проблем рациональной фармакотерапии и фармакоэкономики»РоссияFederal State Budget Scientific Institution I.I. Mechnicov’s Research Institute of Vaccine and Sera; Autonomous non-profit organization “Scientific and Practical Center for the Study of the Problems of Rational Pharmacotherapy and Pharmacoeconomics”Russian Federation201908042020042332Copyright © Зырянов С.К., Дьяков И.Н., 20202020Зырянов С.К., Дьяков И.Н.Zyryanov S.K., Dyakov I.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/482клинико-экономический анализдапаглифлозинанализ влияния на бюджетинтенсификация гипогликемической терапиисахарный диабетclinical and economic analysisdapagliflozinbudget impact analysisintensification of hypoglycemic therapydiabetes mellitusReferencesАлгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. — 9-й выпуск (дополненный). — М.: Сахарный диабет; 2019. DOI:10.14341/DM221S1.Standards of specialized diabetes care. 9th Edition. Ed by Dedov II, Shestakova MV, Mayorov AYu. Moscow: Diabetes mellitus; 2019. (In Russ). DOI:10.14341/DM221S1.Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. // Сахарный диабет. — 2018. — Т. 21. — №3. — С. 144-159. DOI: 10.14341/DM9686.Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AA, Isakov MA. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-159. (In Russ). DOI: 10.14341/DM9686.Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. DOI: 10.1093/eurheartj/ehz486.Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. DOI: 10.1093/eurheartj/ehz486.Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. DOI: 10.2337/dci18-0033.Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. DOI: 10.2337/dci18-0033.Wanner C, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. (2016). DOI:10.1056/NEJMoa1515920.Wanner C, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. (2016). DOI:10.1056/NEJMoa1515920.Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. DOI: 10.1056/NEJMoa1611925.Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. DOI: 10.1056/NEJMoa1611925.Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. DOI: 10.1056/NEJMoa1812389.Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. DOI: 10.1056/NEJMoa1812389.Zelniker TA, et al. Comparison of the Effects of Glucagon-Like Peptide Rece onists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation. 2019 Apr 23;139(17):2022-2031. DOI: 10.1161/CIRCULATIONAHA.118.038868.Zelniker TA, et al. Comparison of the Effects of Glucagon-Like Peptide Rece onists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation. 2019 Apr 23;139(17):2022-2031. DOI: 10.1161/CIRCULATIONAHA.118.038868.Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39. DOI:10.1016/S0140-6736(18)32590-X.Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39. DOI:10.1016/S0140-6736(18)32590-X.McMurray JJV, et al. A trial to evaluate the effect of the sodium—glucose co?transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA?HF). Eur J Heart Fail. 2019 May;21(5):665-675. DOI: 10.1002/ejhf.1432.McMurray JJV, et al. A trial to evaluate the effect of the sodium—glucose co?transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA?HF). Eur J Heart Fail. 2019 May;21(5):665-675. DOI: 10.1002/ejhf.1432.Государственный реестр лекарственных средств. Инструкция по медицинскому применению препарата Форсига (дапаглифлозин), ЛП-002596. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0be604a2-bf33-4a1e-9fd2-4ae2e2066da5&t=. (Accessed: 8th November 2019).Gosudarstvennyj reestr lekarstvennyh sredstv. Instrukciya po medicinskomu primeneniyu preparata Forsiga (dapagliflozin), ЛП-002596. (In Russ). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0be604a2-bf33-4a1e-9fd2-4ae2e2066da5&t=. (Accessed: 8th November 2019).Wilding JP, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):405-15. DOI: 10.7326/0003-4819-1566-201203200-00003.Wilding JP, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):405-15. DOI: 10.7326/0003-4819-1566-201203200-00003.Das G, Surya A & Abusahmin H. Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes. Ther Adv Endocrinol Metab. 2018 25;9(8):269-270. DOI: 10.1177/2042018818771434.Das G, Surya A & Abusahmin H. Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes. Ther Adv Endocrinol Metab. 2018 25;9(8):269-270. DOI: 10.1177/2042018818771434.Persson F, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy?: A multinational observational study. Diabetes Obes Metab. 2018 Feb;20(2):344-351 DOI:10.1111/dom.13077.Persson F, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy?: A multinational observational study. Diabetes Obes Metab. 2018 Feb;20(2):344-351 DOI:10.1111/dom.13077.Gks.ru. Доходы-Федеральная служба государственной стастики.Dohody-Federal’naya sluzhba gosudarstvennoj stastiki. (In Russ)..Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV & Isakov MА. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-159. DOI: 10.14341/DM9686.Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV & Isakov MА. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-159. DOI: 10.14341/DM9686.WHO. Defined Daily Dose (DDD) — WHO: A10A INSULINS AND ANALOGUES. WHO Collaborating Centre for Drug Statistics Methodology (2018). Available at: https://www.whocc.no/atc_ddd_index/?code=A10AE04&showdescription=yes. (Accessed: 28th November 2019).WHO. Defined Daily Dose (DDD) — WHO: A10A INSULINS AND ANALOGUES. WHO Collaborating Centre for Drug Statistics Methodology (2018). Available at: https://www.whocc.no/atc_ddd_index/?code=A10AE04&showdescription=yes. (Accessed: 28th November 2019).Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. DOI: 10.1056/NEJMoa1504720.Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. DOI: 10.1056/NEJMoa1504720.Leiter LA, McGuire DK & Wilding JPH. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Subanalysis From the DECLARETIMI 58 Trial. Circulation. 2019 May 28;139(22):2516-2527 DOI:10.1161/CIRCULATIONAHA.119.039996.Leiter LA, McGuire DK & Wilding JPH. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Subanalysis From the DECLARETIMI 58 Trial. Circulation. 2019 May 28;139(22):2516-2527 DOI:10.1161/CIRCULATIONAHA.119.039996.White WB, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35. DOI:10.1056/NEJMoa1305889.White WB, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35. DOI:10.1056/NEJMoa1305889.Scirica BM, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013 Oct 3;369(14):1317-26. DOI:10.1056/NEJMoa1307684.Scirica BM, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013 Oct 3;369(14):1317-26. DOI:10.1056/NEJMoa1307684.Green JB, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232-42. DOI: 10.1056/NEJMoa1501352.Green JB, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232-42. DOI: 10.1056/NEJMoa1501352.Kostev K, Pscherer S, Rist R, et al. Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study. J Diabetes Sci Technol. 2017 05 4;11(3):590-596.Kostev K, Pscherer S, Rist R, et al. Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study. J Diabetes Sci Technol. 2017 05 4;11(3):590-596.The ORIGIN Trial Investigators, et al. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. DOI: 10.1056/NEJMoa1203858The ORIGIN Trial Investigators, et al. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. DOI: 10.1056/NEJMoa1203858Marso SP, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723-732. DOI: 10.1056/NEJMoa1615692.Marso SP, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723-732. DOI: 10.1056/NEJMoa1615692.Mosenzon O, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes?: an analysis from the DECLARE — TIMI 58 randomised trial. LANCET Diabetes Endocrinol. 2019 Aug;7(8):606-617. DOI: 10.1016/S2213-8587(19)30180-9.Mosenzon O, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes?: an analysis from the DECLARE — TIMI 58 randomised trial. LANCET Diabetes Endocrinol. 2019 Aug;7(8):606-617. DOI: 10.1016/S2213-8587(19)30180-9.Furtado RHM, et al. Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial. Circulation. 2019 May 28;139(22):2516-2527. DOI: 10.1161/CIRCULATIONAHA.119.039996.Furtado RHM, et al. Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial. Circulation. 2019 May 28;139(22):2516-2527. DOI: 10.1161/CIRCULATIONAHA.119.039996.Mcmurray JJV, Ponikowski P, Bolli GB & Lukashevich V. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. JACC: Heart Failure 6(1) 2017. DOI: 10.1016/j.jchf.2017.08.004.Mcmurray JJV, Ponikowski P, Bolli GB & Lukashevich V. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. JACC: Heart Failure 6(1) 2017. DOI: 10.1016/j.jchf.2017.08.004.Nissen SE, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;1—9. DOI: 10.1056/NEJMoa1305889.Nissen SE, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;1—9. DOI: 10.1056/NEJMoa1305889.

The authors declare that there are no conflicts of interest present.